GSE141143 BTK KLHL14 knockout TMD8 1 v 0 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE141143_BTK_KLHL14 knockout_TMD8_1_v_0_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE141143_BTK_KLHL14 knockout_TMD8_1_v_0_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE141143_BTK_KLHL14 knockout_TMD8_1_v_0_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE141143_BTK_KLHL14 knockout_TMD8_1_v_0_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

Rho GTPase activating protein 23

Gene

long intergenic non-protein coding RNA 1138

Gene

nicotinamide phosphoribosyltransferase pseudogene 1

Gene

MIR155 host gene

Gene

long intergenic non-protein coding RNA 2889

Gene

uncharacterized LOC101927888

Gene

acetylserotonin O-methyltransferase

Gene

MIR3945 host gene

Gene

long intergenic non-protein coding RNA 1943

Gene

OXCT1 antisense RNA 1

  • Gene

    Rho GTPase activating protein 23


  • Gene

    long intergenic non-protein coding RNA 1138


  • Gene

    nicotinamide phosphoribosyltransferase pseudogene 1



  • Gene

    long intergenic non-protein coding RNA 2889


  • Gene

    uncharacterized LOC101927888


  • Gene

    acetylserotonin O-methyltransferase



  • Gene

    long intergenic non-protein coding RNA 1943


  • Gene

    OXCT1 antisense RNA 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.